EBMT-EHA CAR-T 2019 | Working together – CAR T-cell logistics

Antonio Pagliuca

The complexities of CAR T-cell therapy logistics and the union required between industry and clinicians to ensure the best outcomes for patients is discussed by Antonio Pagliuca, MBBS King’s College NHS Foundation Trust, London, London, UK, at the 1st European CAR T-Cell Meeting, held in Paris, France, co-organized by the European Society for Blood & Marrow Transplantation (EBMT) and the European Hematology Association (EHA).

Transcript (edited for clarity):

So each of the companies has a slightly different chain of custody process, if I can use that term. So of course the patient and the center are suppliers of the base product, ie. the T cells, that are either shipped to a center outside the UK. In fact, the current Helio product is shipped to Amsterdam and then it shipped to the United States. The Novartis product, we collect the cells locally, but then the cells are frozen before they’re shipped on for production, currently in the United States. So it’s created a whole new regulatory pathway that has meant that we’ve had to work quite closely with the companies. They’ve onboarded us, they understand how we function, we now understand how they function. And together we’re making sure that there is a product that is safely collected, delivered to the company, effectively produced Car T product and delivered back to us, in both settings as a frozen product. And that can, in parallel, be set up to ensure that the timing and admission of the patient to receive those cells is done, and hopefully the outcome is positive.

Share this video